Designing a new drug for chronic pain

August 24, 2012
Designing a new drug for chronic pain

(Medical Xpress)—Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded £1.4 million to design a new drug for the treatment of chronic pain.

The project funded by the Medical Research Council (MRC), addresses the long-standing and urgent need for effective therapies for chronic pain which affects around 20% of adults in Europe and the US, and more than eight million adult patients in the UK alone. Medication currently available to treat the condition is effective in only around 40% of sufferers and even these patients often struggle to maintain the balance between adequate pain relief and the adverse effects of current therapies.

Targeting the glycine receptor

The research team is examining compounds which target the glycine receptor, one of the principal inhibitory neuronal receptors in the central nervous system and crucial in the sensation of chronic pain. Through medicinal chemistry, computational methods and experimental testing, scientists successfully identified novel compounds which could be used for the treatment of chronic pain without unwanted sedative effects.

Professor Martin Leuwer, from the University's Department of Molecular and Clinical Pharmacology in the Institute of Translational Medicine, said: "This is an exciting project that expands our drug discovery portfolio into a new therapeutic area with a huge unmet medical need.  Our collaborative team of medicinal chemists, molecular modellers and neurobiologists have made significant advances in this area and this funding provides us with the opportunity to drive the project forward towards an entirely new class of drug for the treatment of chronic pain conditions. 

"We're aiming to develop molecules that target the glycine receptor, into a drug that can be administered as a tablet. Our project concept has been shown to work but further improvements are required if we are to reach the goal of generating a drug which is safe, effective and orally viable. Our ultimate aim is to allow chronic pain patients to regain a dramatically improved quality of life."

He added: "In view of the huge numbers of patients worldwide whose lives are wrecked by chronic pain, the fact that current treatment options are clearly insufficient and the dramatic toll on economies caused by millions of lost working hours, our causal treatment option has the potential to have a tremendous beneficial impact on individuals and societies."

Explore further: Naturally occurring protein has a role in chronic pain

Related Stories

Naturally occurring protein has a role in chronic pain

June 12, 2012
Researchers in France and Sweden have discovered how one of the body's own proteins is involved in generating chronic pain in rats. The results, which also suggest therapeutic interventions to alleviate long-lasting pain, ...

Chronic pain gene identified

September 8, 2011
British researchers say they have identified the gene that controls chronic pain, opening the door to new drug therapies that block the chemical processes that cause chronic back pain, headaches or arthritis.

Study suggests new way to treat chronic pain

March 26, 2012
Nearly one in five people suffers from the insidious and often devastating problem of chronic pain.

Recommended for you

Estrogen discovery could shed new light on fertility problems

December 12, 2017
Estrogen produced in the brain is necessary for ovulation in monkeys, according to researchers at the University of Wisconsin-Madison who have upended the traditional understanding of the hormonal cascade that leads to release ...

Time of day affects severity of autoimmune disease

December 12, 2017
Insights into how the body clock and time of day influence immune responses are revealed today in a study published in leading international journal Nature Communications. Understanding the effect of the interplay between ...

3-D printed microfibers could provide structure for artificially grown body parts

December 12, 2017
Much as a frame provides structural support for a house and the chassis provides strength and shape for a car, a team of Penn State engineers believe they have a way to create the structural framework for growing living tissue ...

Team identifies DNA element that may cause rare movement disorder

December 11, 2017
A team of Massachusetts General Hospital (MGH) researchers has identified a specific genetic change that may be the cause of a rare but severe neurological disorder called X-linked dystonia parkinsonism (XDP). Occurring only ...

Protein Daple coordinates single-cell and organ-wide directionality in the inner ear

December 11, 2017
Humans inherited the capacity to hear sounds thanks to structures that evolved millions of years ago. Sensory "hair cells" in the inner ear have the amazing ability to convert sound waves into electrical signals and transmit ...

Gene therapy improves immunity in babies with 'bubble boy' disease

December 9, 2017
Early evidence suggests that gene therapy developed at St. Jude Children's Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.